NasdaqHealth CarePharmaceutical PreparationsNEW YORK, NY

XTL Biopharmaceuticals Ltd. XTLB

Ask your AI

A stock split around the filing date makes the share count unclearCIK 1023549

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

2 added · 0 trimmed

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

What changed in XTL Biopharmaceuticals Ltd.'s latest quarterly report, compared with the one before.

We have not read a recent 10-Q for this company yet.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No recent insider purchases or sales for this company.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

7,298 shares

2 funds report XTLB. Values checked against market prices.

Q3 2026. 0 new, 2 added to, 0 trimmed, 1 exited since Q2 2026.

Top 13F holders
#
1	Rhumbline Advisers 13F ↗	6,871	$16.5K	+10.3%
2	UBS Group AG 13F ↗	427	$983	+241.6%

Download CSV Every fund that holds XTLB, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What XTL Biopharmaceuticals Ltd. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What XTL Biopharmaceuticals Ltd. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2026	6	—	72,702	$175.4K
Q2 2026	3	-3	7,566	$20.7K
Q3 2026	2	-1	7,298	$17.5K

Each point is a quarter-end, from Q1 2026 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (98386D406). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2026) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakesNone in 12 mo 8-K eventsNone in 90 days Patents10 patents granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials2 active IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: XTL BIOPHARMACEUTICALS LTD
Address: XTL BIOPHARMACEUTICALS LTD, C/O ALSTON & BIRD LLP, 90 PARK AVENUE, NEW YORK, NY 10016
Phone: 972 9 955 7080
Filer category: Non-accelerated filer
Incorporated in: Israel
Listed as: XTLB (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$1.60−$0.04 (−2.44%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $1.53 · High $2.02Nov 13, 2026

Aug 13, 2026Low $1.53 · High $3.23Nov 13, 2026

Nov 13, 2025Low $1.53 · High $4.28Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. The stock split 1-for-4 on Mar 25, 2026; earlier prices are shown divided by the split ratio. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.